Efficacy and safety of Etanercept therapy in juvenile idiopathic arthritis
نویسندگان
چکیده
Methods The study included data from out-patient medical record on 69 JIA patients (45 children, 24 adults) who received ETN therapy during 2004 till 2010. Treatment efficacy was assessed using the ACR (American College of Rheumatology) Pedi 30, 50 and 70 response. Therapy was evaluated after 3, 6, 12 and 24 months (mo) of ETN treatment. Safety was assessed by recording ETN adverse events (AE). Statistical data analysis was made using Friedman, Kolmogorov-Smirnov and Pearson’s chi-square tests.
منابع مشابه
No benefit of the combination therapy etanercept and methotrexate compared to etanercept mono therapy in juvenile idiopathic arthritis – a matched pair analysis
Methods A cohort of 1190 JIA patients enrolled in the German JIA Enbrel registry has been used for screening. Matching criteria included JIA subtype, gender, disease duration, use of corticosteroids, oligoversus polyarthritis at therapy start and the sedimentation rate. Efficacy was determined using the PedACR 30/ 50 and 70 response criteria. Safety assessments were based on adverse events repo...
متن کاملLong-term experience with biologic therapies for the treatment of polyarticular juvenile idiopathic arthritis
The introduction of biological therapies opened a new era for the treatment of polyarticular juvenile idiopathic arthritis. Remission of disease is now a goal well within reach for many patients. It is now more than a decade since the first biologics for treatment of pediatric rheumatic disease were approved. Long-term effects regarding safety and efficacy are of great interest and these data a...
متن کاملClinical utility of etanercept in the treatment of arthritides in children and adolescents
Juvenile idiopathic arthritis (JIA) is a group of chronic inflammatory diseases affecting approximately 300,000 children and adolescents in the United States of unknown cause. It can affect children from the age of 0 years up to the age of 16 years. The International League of Associations of Rheumatology has defined seven subsets of JIA based on several factors including the number of affected...
متن کاملSafety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis.
OBJECTIVES Etanercept, a recombinant TNF receptor fusion protein, has been approved for the treatment of resistant polyarticular course juvenile idiopathic arthritis at a dosage of 0.4 mg/kg twice weekly in children older than 4 years. In adult patients, efficacy and safety of etanercept 25 mg twice weekly was comparable with 50 mg once weekly. Therefore, safety and efficacy of etanercept once ...
متن کاملEtanercept treatment in juvenile idiopathic arthritis: The Polish registry
BACKGROUND To evaluate the long-term safety and efficacy of etanercept treatment in Polish patients with juvenile idiopathic arthritis (JIA). MATERIAL/METHODS The study involved patients, fulfilling the JIA criteria of the International League of Associations of Rheumatology (ILAR), who were started on etanercept therapy after methotrexate and other synthetic disease-modifying antirheumatic d...
متن کامل